This study is testing a drug called pemigatinib for adults with advanced or metastatic pancreatic cancer. This means the cancer has spread from its original spot to other parts of the body. The study focuses on people whose cancer is caused by changes in a gene called FGFR (fibroblast growth factor receptor). These changes can help cancer grow, and researchers want to see if pemigatinib can block these changes and stop the cancer from growing.

Participants will take pemigatinib by mouth once daily for 14 days in each 21-day cycle. Doctors will use tests like CT or MRI scans to check if the treatment works. The study lasts until the disease gets worse or there are serious side effects.

• Study requires blood samples and regular imaging tests.
• Participants must have tried at least one other standard treatment.
• Excludes people with certain other health conditions or treatments.

This study is conducted via telemedicine, meaning you can participate from home with fewer hospital visits. It's important to discuss with your doctor if this is right for you.